MeiraGTx Holdings PLC
NASDAQ:MGTX

Watchlist Manager
MeiraGTx Holdings PLC Logo
MeiraGTx Holdings PLC
NASDAQ:MGTX
Watchlist
Price: 8 USD -1.23%
Market Cap: $643.9m

Operating Margin

-597.9%
Current
Improving
by 501.9%
vs 3-y average of -1 099.8%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-597.9%
=
Operating Income
$-163.9m
/
Revenue
$27.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-597.9%
=
Operating Income
$-163.9m
/
Revenue
$27.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
MeiraGTx Holdings PLC
NASDAQ:MGTX
643.8m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
392.6B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
171.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.6B USD
Loading...

Market Distribution

Lower than 91% of companies in the United States of America
Percentile
9th
Based on 14 112 companies
9th percentile
-597.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

MeiraGTx Holdings PLC
Glance View

Market Cap
643.9m USD
Industry
Biotechnology

MeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. The company is headquartered in New York City, New York and currently employs 287 full-time employees. The company went IPO on 2018-06-08. The firm is focused on three areas of unmet medical needs, including inherited retinal diseases (IDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. The Company’s products pipeline includes AAV-RPGR, which is for the treatment of x-linked retinitis pigmentosa (XLRP); AAV-hAQP1, which is for the treatment of grade two/three radiation-induced xerostomia; AAV-GAD, is for the treatment of Parkinson’s disease, and AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia (ACHM). The firm has six programs in clinical development, including Phase I/Il clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa and RPE65-Deficiency, and Phase I clinical trials for radiation-induced xerostomia (RIX), and a Parkinson’s program that has completed a Phase II trial with published data.

MGTX Intrinsic Value
5.94 USD
Overvaluation 26%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-597.9%
=
Operating Income
$-163.9m
/
Revenue
$27.4m
What is MeiraGTx Holdings PLC's current Operating Margin?

The current Operating Margin for MeiraGTx Holdings PLC is -597.9%, which is above its 3-year median of -1 099.8%.

How has Operating Margin changed over time?

Over the last 3 years, MeiraGTx Holdings PLC’s Operating Margin has decreased from -196.4% to -597.9%. During this period, it reached a low of -2 083.9% on Jun 30, 2024 and a high of -196.4% on Sep 30, 2022.

Back to Top